Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Paper
  • Published:

Chronic myeloid leukaemia: an investigation into the role of Bcr-Abl-induced abnormalities in glucose transport regulation

Abstract

In chronic myeloid leukaemia (CML) expression of the chimeric tyrosine kinase, Bcr-Abl, promotes the inappropriate survival of haemopoietic stem cells by a nonautocrine mechanism in the absence of IL-3. Stimulation of glucose uptake appears to play an important role in the suppression of apoptosis by this cytokine in normal haemopoietic cells. To investigate whether the cell survival mechanisms mediated by the oncoprotein and cytokine showed any similarities, we employed a haemopoietic cell line, TonB210, engineered for inducible expression of Bcr-Abl. Tyrosine kinase expression in cytokine-deprived cells was found to mimic the effect of IL-3 in maintaining a higher Vmax for hexose uptake. In both IL-3- treated cells and those expressing Bcr-Abl, high rates of hexose uptake were associated with the retention at the cell surface of approximately 80% of the total cellular content of the GLUT1 glucose transporter. In contrast, treatment of Bcr-Abl-expressing cells for 6 h with the Bcr-Abl kinase inhibitor Glivec (10 μ M), in the absence of IL-3, led to internalization of approximately 90% of the cell-surface transporters and drastically decreased (4.4±0.9 (mean±s.e.m., 4)-fold) the Vmax for hexose uptake, without significant effect on the Km for this process or on the total cellular transporter content. These effects were not the result of any significant loss in cell viability, and preceded the onset of apoptosis caused by inhibition of Bcr-Abl. Both IL-3 treatment and expression of Bcr-Abl led to enhanced phosphorylation of Akt (protein kinase B). The stimulation of transport by IL-3 and Bcr-Abl in TonB210 cells was inhibitable by phosphatidylinositol 3-kinase inhibitors, indicating the involvement of this kinase in the signal transduction pathway. These findings suggest that inhibition of glucose transport plays an important role in the therapeutic action of Glivec, and that the signal transduction pathways involved in transport stimulation by Bcr-Abl may offer novel therapeutic targets for CML.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6
Figure 7

Similar content being viewed by others

References

  • Azam M, Latek RR and Daley GQ . (2003). Cell, 112, 831–843.

  • Bentley J, Itchayanan D, Barnes K, McIntosh E, Tang X, Downes CP, Holman GD, Whetton AD, Owen-Lynch PJ and Baldwin SA . (2003). J. Biol. Chem., 278, 39337–39348.

  • Bentley J, Walker I, McIntosh E, Whetton AD, Owen-Lynch PJ and Baldwin SA . (2001). Br. J. Haematol., 112, 212–215.

  • Berridge MV, Horsfield JA and Tan AS . (1995). J. Cell Physiol., 163, 466–476.

  • Boren J, Cascante M, Marin S, Comin-Anduix B, Centelles JJ, Lim S, Bassilian S, Ahmed S, Lee WNP and Boros LG . (2001). J. Biol. Chem., 276, 37747–37753.

  • Cambier N, Chopra R, Strasser A, Metcalf D and Elefanty AG . (1998). Oncogene, 16, 335–348.

  • Chapman RS, Gregory CD and Dive C . (1996). Hematopoietic cell growth factors and their receptors. Whetton AD, Gordon J (eds). Plenum Press: New York, pp. 151–201.

    Google Scholar 

  • Chopra R, Pu QQ and Elefanty AG . (1999). Blood Rev., 13, 211–229.

  • Davies A, Ciardelli TL, Lienhard GE, Boyle JM, Whetton AD and Baldwin SA . (1990). Biochem. J., 266, 799–808.

  • Dorsey JF, Cunnick JM, Lanehart R, Huang M, Kraker AJ, Bhalla KN, Jove R and Wu J . (2002). Leukemia, 16, 1589–1595.

  • Druker BJ . (2002). Oncogene, 21, 8541–8546.

  • Druker BJ . (2004). Adv. Cancer Res., 91, 1–30.

  • Druker BJ, Tamura S, Buchdunger E, Ohno S, Segal GM, Fanning S, Zimmermann J and Lydon NB . (1996). Nat. Med., 2, 561–566.

  • Gottschalk S, Anderson N, Hainz C, Eckhardt SG and Serkova NJ . (2004). Clin. Cancer Res., 10, 6661–6668.

  • Heyworth CM, Whetton AD, Nicholls S, Zsebo K and Dexter TM . (1992). Blood, 80, 2230–2236.

  • Hoover RR, Gerlach MJ, Koh EY and Daley GQ . (2001). Oncogene, 20, 5826–5835.

  • Jiang X, Lopez A, Holyoake T, Eaves A and Eaves C . (1999). Proc. Natl. Acad. Sci. USA, 96, 12804–12809.

  • Kan O, Baldwin SA and Whetton AD . (1994). J. Exp. Med., 180, 917–923.

  • Kansara M and Berridge MV . (2004). Exp. Cell Res., 293, 321–330.

  • Karnauskas R, Niu Q, Talapatra S, Plas DR, Greene ME, Crispino JD and Rudin CM . (2003). Oncogene, 22, 688–698.

  • Klucher KM, Lopez DV and Daley GQ . (1998). Blood, 91, 3927–3934.

  • Koury MJ and Bondurant MC . (1990). Science, 248, 378–381.

  • Li S, Gillessen S, Tomasson MH, Dranoff G, Gilliland DG and Van Etten RA . (2001). Blood, 97, 1442–1450.

  • Marley SB, Lewis JL, Schneider H, Rudd CE and Gordon MY . (2004). Br. J. Haematol., 125, 500–511.

  • McCoy KD, Ahmed N, Tan AS and Berridge MV . (1997). J. Biol. Chem., 272, 17276–17282.

  • Nagar B, Bornmann WG, Pellicena P, Schindler T, Veach DR, Miller WT, Clarkson B and Kuriyan J . (2002). Cancer Res., 62, 4236–4243.

  • Nefesh I, Bauskin AR, Alkalay I, Golembo M and Ben-Neriah Y . (1991). Int. Immunol., 3, 827–831.

  • Owen PJ, Musk P, Evans CA and Whetton AD . (1993). J. Biol. Chem., 268, 15696–15703.

  • Pierce A, Owen-Lynch PJ, Spooncer E, Dexter TM and Whetton AD . (1998). Oncogene, 17, 667–672.

  • Plas DR, Talapatra S, Edinger AL, Rathmell JC and Thompson CB . (2001). J. Biol. Chem., 276, 12041–12048.

  • Schindler T, Bornmann W, Pellicena P, Miller WT, Clarkson B and Kuriyan J . (2000). Science, 289, 1938–1942.

  • Shtivelman E, Lifshitz B, Gale RP and Canaani E . (1985). Nature, 315, 550–554.

  • Skorski T, Bellacosa A, NieborowskaSkorska M, Majewski M, Martinez R, Choi JK, Trotta R, Wlodarski P, Perrotti D, Chan TO, Wasik MA, Tsichlis PN and Calabretta B . (1997). EMBO J., 16, 6151–6161.

  • Tang X, Downes CP, Whetton AD and Owen-Lynch PJ . (2000). J. Biol. Chem., 275, 13142–13148.

  • Vander Heiden MG, Plas DR, Rathmell JC, Fox CJ, Harris MH and Thompson CB . (2001). Mol. Cell Biol., 21, 5899–5912.

  • Williams GT, Smith CA, Spooncer E, Dexter TM and Taylor DR . (1990). Nature, 343, 76–79.

Download references

Acknowledgements

This work was supported by grants from the Yorkshire Cancer Research, the Wellcome Trust and the Leukaemia Research Fund.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Kay Barnes.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Barnes, K., McIntosh, E., Whetton, A. et al. Chronic myeloid leukaemia: an investigation into the role of Bcr-Abl-induced abnormalities in glucose transport regulation. Oncogene 24, 3257–3267 (2005). https://doi.org/10.1038/sj.onc.1208461

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1208461

Keywords

This article is cited by

Search

Quick links